Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 7/20 | 0.49 |
| ▸ | CTSL | P07711 | 7/20 | 0.49 |
| ▸ | CTSS | P25774 | 3/20 | 0.47 |
| ▸ | CTSK | P43235 | 3/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.47 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27428952 | 1.00 | CTSB (0.49) | CTSBCTSLCTSSCTSKCYP3A4 | |
| SCHEMBL27428885 | 0.96 | CTSB (0.49) | CTSBCTSLCTSSCTSKCYP3A4 | |
| SCHEMBL30918356 | 0.90 | CTSL (0.49) | CTSBCTSLCTSSCTSKCYP3A4 | |
| SCHEMBL27428946 | 0.90 | CTSL (0.49) | CTSBCTSLCTSSCTSKCYP3A4 | |
| SCHEMBL30918338 | 0.87 | CTSL (0.55) | CTSBCTSLCTSSCTSK | |
| SCHEMBL27428889 | 0.86 | CTSL (0.48) | CTSBCTSLCTSSCTSKCYP3A4 | |
| SCHEMBL27428881 | 0.85 | LMNA (0.41) | KMT2A | |
| SCHEMBL27389417 | 0.84 | LMNA (0.40) | CTSBCTSLKMT2A | |
| SCHEMBL30724708 | 0.83 | BACE1 (0.45) | — | |
| SCHEMBL30918324 | 0.82 | LMNA (0.42) | CYP3A4KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4622991-A2 | SYNTHESIS OF A CYCLIC PEPTIDE | Janssen Pharmaceutica NV (BE) | 2025-10-01 | — | — | EP | disclosed |
| US-20240218014-A1 | SYNTHESIS OF A CYCLIC PEPTIDE | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240218014-A1 | SYNTHESIS OF A CYCLIC PEPTIDE | VIP, QPCT, PTMS | CTSB 1288/4885CTSL 743/4885CTSS 1182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.